

Composite Analysis of the Finances for Twelve of the World's Largest Pharmaceutical Companies from 2003-2015

By David Belk MD

The twelve companies are: Abbot/AbbVie, Amgen, AstraZeneca, Bristol-Myer Squibb, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer and Roche. Together, these twelve companies earned roughly 40% of the world's total pharmaceutical revenue in recent years.

Financial summaries for each company can be found here:
http://truecostofhealthcare.net/pharmaceutical_financial_index/

Here are the composite numbers for all 12 companies from 2003-2015:

Total Revenue (Sales):	\$5,353 Billion
Total Profit:	\$1,053 Billion
Total Spent on Research:	\$887 Billion
Total Spent on Marketing:	\$1,588 Billion
Total Spent in Taxes:	\$282 Billion
US Revenue:	\$2,466 Billion
Revenue from All Other Countries:	\$2,887 Billion

Here are the composite numbers for all 12 companies for 2015 only:

Total Revenue (Sales):	\$449 Billion
Total Profit:	\$108 Billion
Total Spent on Research:	\$77 Billion
Total Spent on Marketing:	\$125 Billion
Total Spent in Taxes:	\$22 Billion
US Revenue:	\$211 Billion
Revenue from All Other Countries:	\$238 Billion




Figure 1: Total amount all 12 companies earned in profit (net income after taxes) from 2003-2015 compared to how much they spent on research, marketing and taxes.





Figure 2: Total amount all 12 companies earned in profit (net income after taxes) in only 2015 compared to how much they spent on research, marketing and taxes.

Proportional Allocation of Revenue 2003-2015



Figures 3&4: The proportion of the total revenue for all twelve companies that was allocated toward research, marketing, taxes and profits from 2003-2015 (above) and for 2015 only (below).

Proportional Allocation of Revenue 2015 Only






Figure 5: Profits for all twelve companies compared with amount spent on research, marketing and taxes each year from 2003-2015.

Proportion of Revenue from US vs. All Other Countries 2003-2015




Figure 6: 46% of the combined revenue for these 12 companies since 2003 has come from sales in the US.

Proportion of Revenue from US vs. All Other Countries 2015 Only




Figure 7: 47% of the combined revenue for these 12 companies in just 2015 came from sales in the US.




Figure 8: Total revenues for most of the major pharmaceutical companies have been surprisingly flat since about 2008. This is in spite of the fact that the prices of almost all brand name medications have gone up dramatically in the US.

<http://truecostofhealthcare.net/brand-name-medication-prices/>